Johnson & Johnson: Subcutaneous amivantamab delivers promising 45 percent overall response ...

Responses were rapid and durable, and tumor shrinkage was observed in 82 percent of patients New findings from this investigational study build on the strength ...
The Malaysian Reserve

Alphamab Oncology Presented Multiple Clinical Data on Biparatopic HER2-targeting ADC ...

Title: Biparatopic anti-HER2 antibody drug conjugate (ADC) JSKN003 in the treatment of primary platinum-refractory ovarian cancer (OC) Presentation Number: 1079P Onsite Poster display date: Saturday, ...